Our commitment
Oranda Therapeutics Limited (“Oranda”) is committed to preventing acts of modern slavery and human trafficking from occurring within its business and supply chains. We recognise our responsibility to tackle this issue proactively and to take a robust approach through our internal policies and supply chain due diligence.
This first statement has been prepared voluntarily, with reference to section 54 of the Modern Slavery Act 2015, and in support of NHS procurement, investor, and stakeholder expectations. It sets out actions to understand all potential modern slavery risks related to our business and to put in place steps aimed at ensuring that there is no slavery or human trafficking in our own business or our supply chains.
As Oranda grows, it intends to strengthen its policies, supplier due diligence processes and monitoring arrangements proportionately and practically, reflecting the nature, scale and maturity of the organisation.
As Oranda grows, we want responsible business practice to be built in from the start. Our purpose is to improve access to rare disease medicines, and that responsibility extends to how we work with partners, manage our supply chain and uphold human rights.
John Irwin CCO & Co-Founder, Oranda Therapeutics
At a glance
A summary of our operating model, governance approach, supply chain and commitment to continuous improvement.
Small, remote-first team
Limited direct operational footprint and no directly controlled manufacturing, warehousing or laboratory assets.
Key supply chain
Our manufacturing and distribution partners operate in accordance with applicable regulatory requirements.
Board-level supplier approval
Supplier approval is overseen at Board level, supporting accountability for responsible supply-chain governance.
First-year statement
This is Oranda's first modern slavery statement and establishes the baseline for future improvement, supported by a 12-month plan to strengthen supplier due diligence, controls and review.
Our business and operating model
Oranda is a rare-disease pharmaceutical company focused on improving patient access to affordable rare disease medicines. Oranda is in the early stages of operational development. It currently operates through a lean organisational model, with a small team and a predominantly remote-working structure.
Oranda’s business model relies on specialist third-party partners for key elements of pharmaceutical manufacture, testing, release, logistics, warehousing and distribution. This makes responsible supplier selection, oversight and governance important areas of focus for Oranda’s modern slavery and wider ESG approach.
Our supply chain
Oranda operates in a highly regulated pharmaceutical environment. Manufacturing and distribution partners are expected to operate in accordance with applicable regulatory requirements, including EMA, MHRA, Good Manufacturing Practice and Good Distribution Practice standards where relevant. These controls support supply chain governance, quality and patient safety.
Oranda recognises, however, that modern slavery, human rights and labour standards require specific and proportionate due diligence alongside regulatory compliance.
- 01 Active Pharmaceutical Ingredient suppliers
- 02 Contract Manufacturing Organisations
- 03 Quality release and regulatory partners
- 04 Stockholding and distribution partners
- 05 Logistics partners
- 06 Healthcare system supply
Where the risk sits
Modern slavery risk is currently greatest in outsourced supply chain activities, rather than Oranda's direct operations.
Direct workforce
Contractors (UK & EU)
Third-party manufacturing
Non-European supply chain partners
Lower-tier suppliers
Subcontracted labour and supplier recruitment practices
Risk assessment detail
| Area | Current view | Why | Action |
|---|---|---|---|
| Direct workforce | Low | Small, skilled, remote-first team | Maintain ethical employment practices |
| Contractors (UK & EU) | Low | Professional services support | Include expectations in contractor terms |
| Manufacturing | Medium | Third-party manufacture outside the UK/EU | Request supplier labour and ESG information proportionally from higher-risk suppliers |
| Logistics / warehousing | Medium | Third-party stockholding and distribution | Review policies and contractual controls |
| Lower-tier suppliers | To be reviewed | Limited current visibility beyond direct partners | Improve supplier mapping |
Oranda's direct operational risk is currently low, while the priority is strengthening visibility and controls across key supply chain partners.
Our due diligence process
Oranda will apply supplier due diligence proportionately, prioritising higher-value, higher-risk and business-critical supplier relationships, particularly those involving manufacturing, distribution, logistics, stockholding or non-European supply chain activity. Oranda's current and proposed due diligence activities include the following steps:
-
1
Identify
Supplier register
Confirm key suppliers and their role in the supply chain.
-
2
Prioritise
Risk rating
Rate suppliers by geography, activity and importance to supply.
-
3
Request
Supplier questionnaire
Where relevant, ask for modern slavery, labour, ESG and governance information.
-
4
Review
Due diligence record
Review responses and identify gaps.
-
5
Engage & improve
Improvement notes
Discuss gaps, agree on proportionate next steps and review over time.
Supplier contract controls
For new supplier contracts and contract renewals, Oranda will seek to include appropriate modern slavery, ethical business and responsible labour expectations where relevant and proportionate.
For existing contracts, Oranda may seek non-contractual alignment through supplier expectations, codes of conduct, policy sharing or supplier engagement where appropriate.
Where gaps or concerns are identified, Oranda will seek to understand the issue and engage with the supplier on proportionate next steps. Any response will take into account patient access, product quality, and continuity of medicines supply. Serious or unresolved concerns may be escalated to senior leadership or the Board.
Policy controls
A proportionate governance stack for Oranda's modern slavery and ESG approach.
- Board oversight
- Modern Slavery Statement
- ESG Policy
- Supplier Due Diligence Process
- Supplier Code of Conduct / Supplier Expectations
- Contract clauses
- Training and awareness
- Reporting and escalation
Training, awareness and reporting concerns
Oranda will provide proportionate modern slavery and ESG awareness to the Board, employees, consultants and contractors involved in supplier selection, supplier management, procurement, regulatory activity and ESG matters. As the organisation grows, training will be reviewed and developed to reflect Oranda’s operating model, supply chain and risk profile.
Oranda will encourage concerns relating to modern slavery, human trafficking, labour standards or unethical supplier conduct to be raised with senior leadership or the Board. As Oranda develops its ESG and supplier governance framework, it will confirm appropriate reporting and escalation arrangements.
Measuring effectiveness
Given Oranda's current stage of development, this statement establishes an initial baseline for modern slavery and supply chain governance. Oranda will review the effectiveness of its approach annually. Initial indicators include:
| Indicator | 2026 baseline | 12-month aim |
|---|---|---|
| Key direct suppliers identified | Initial direct suppliers known | Maintain supplier register |
| ESG / supplier due diligence owner assigned | To be confirmed | Confirm owner |
| Supplier expectations developed | Not yet in place | Develop and consider sharing with priority suppliers where relevant |
| Modern Slavery Statement reviewed by Board | Initial statement | Annual Board review |
| Supplier due diligence approach | Developing | Develop proportionate approach for higher-value, higher-risk or business-critical suppliers |
12-month improvement plan
Over the next 12 months, Oranda intends to:
-
1
Approve statement and confirm ESG / supplier due diligence owner
Output: Board-approved statement and named owner
-
2
Maintain a register of priority suppliers and develop supplier expectations
Output: Supplier register and supplier expectations document
-
3
Share expectations with priority suppliers where relevant and proportionate
Output: Supplier engagement record
-
4
Review progress and update statement
Output: Annual Board review and 2027 statement
Closing statement
At the date of this statement, Oranda is not aware of any modern slavery or human trafficking concerns within its direct operations or known supply chain.
Oranda recognises that modern slavery risk can be hidden and will continue to strengthen its approach as the business grows.
If Oranda identifies an actual or suspected modern slavery concern, it will seek to understand the issue, protect affected individuals where relevant, engage with the supplier, and agree on appropriate corrective actions.
Oranda will avoid abrupt action that could worsen harm to workers, while reserving the right to escalate, suspend or terminate supplier relationships where serious or unresolved concerns remain.
Board approval
This statement has been approved by the Board of Directors of Oranda Therapeutics Limited and will be reviewed annually.
OTD-NP-GBR-00049 | August 2026